Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vanda Pharmaceuticals (VNDA) Leases (2019 - 2025)

Vanda Pharmaceuticals' Leases history spans 7 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Leases rose 48.55% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, up 48.55%, while the annual FY2025 figure was $7.3 million, 48.55% up from the prior year.
  • Leases for Q4 2025 was $7.3 million at Vanda Pharmaceuticals, up from $5.1 million in the prior quarter.
  • Across five years, Leases topped out at $10.2 million in Q1 2021 and bottomed at $4.8 million in Q2 2025.
  • The 5-year median for Leases is $7.6 million (2023), against an average of $7.5 million.
  • The largest annual shift saw Leases plummeted 30.41% in 2024 before it soared 48.55% in 2025.
  • A 5-year view of Leases shows it stood at $9.3 million in 2021, then dropped by 9.4% to $8.4 million in 2022, then decreased by 15.44% to $7.1 million in 2023, then tumbled by 30.41% to $4.9 million in 2024, then skyrocketed by 48.55% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Leases are $7.3 million (Q4 2025), $5.1 million (Q3 2025), and $4.8 million (Q2 2025).